Delay of treatment change following objective progression on first-line erlotinib in EGFR-mutant lung cancer

BACKGROUND: Erlotinib is a highly active EGFR kinase inhibitor approved for first-line use in lung cancers harboring EGFR mutations. Anecdotal experience suggests this drug may provide continued disease control following objective progression of disease (PD), however this has not been systematically...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer
Autores principales: Lo, Peter C., Dahlberg, Suzanne E., Nishino, Mizuki, Johnson, Bruce E., Sequist, Lecia V., Jackman, David M., Jänne, Pasi A, Oxnard, Geoffrey R.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4525718/
https://ncbi.nlm.nih.gov/pubmed/25876525
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29397
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares